Edge Therapeutics (EDGE) Reports Q3 Loss of $7.08

Edge Therapeutics Reports Third Quarter 2015 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced financial results and highlights for the three months ended September 30, 2015.

This has been a remarkable year so far, during which Edge has achieved several significant regulatory and corporate milestones, said Brian A. Leuthner, Edges President and Chief Executive Officer.  We continue to make tremendous progress with EG-1962, our lead product, including reporting positive results from our Phase 1/2 NEWTON study;... More

Hercules Announces Third Quarter 2015 Financial Results and Quarterly Dividend of $0.31 per Share

Q3 2015 Distributable Net Operating Income, or DNOI, of $25.8 million, or $0.36 per share, up 35.3% and 33.3% quarter-over-quarter, respectively Q3 2015 Net Investment Income, NII of $23.6 million, or $0.33 per share, up 40.6% and 43.5% quarter-over-quarter, respectively New Equity and Debt Commitments year-to-date of $628.9 million Total Gross Fundings year-to-date totaled $532.0 million, a 28.7% increase over the same period in 2014 Record Q3 Fundings of $158.6 million, an increase of 23.3% compared to the $128.6 million in Q3 2014, making Q3 2015 the best Q3 in the Company history... More